Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-World study tracks Benralizumab's impact on severe asthma in china

NCT ID NCT06862206

Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jul 23, 2026 · Updated 3 times

Summary

This study follows 1,000 people aged 12 and older in China who have severe eosinophilic asthma and are prescribed benralizumab. Researchers will track how well the drug controls asthma symptoms over time using questionnaires, and note reasons for stopping or switching treatment. The goal is to understand how benralizumab works in everyday medical practice, not in a controlled lab setting.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
benralizumab
What this could lead to
If successful, this study could provide real-world evidence on how well benralizumab controls severe asthma in Chinese patients, helping doctors tailor treatment.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by patient selection or other factors. It does not test a new treatment or prove cause and effect.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2025

Expected to finish

Jan 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

severe eosinophilic asthma

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria -Patients are eligible to be included in the study only if all of the following criteria apply: * Patients must to be 12 years old (inclusive) at the time of signing the informed consent. * Patients with severe eosinophilic asthma prescribed with benralizumab at the discretion of the clinician. * Blood EOS≥150/ul in the 3 months prior to or EOS≥300/ul in the 1 year prior to the time of signing the informed consent. * Participating patients and/or their legally authorized representative must provide signed and dated written informed consent form prior to any study specific procedures. Exclusion criteria -Patients should not enter the study if any of the following exclusion criteria are fulfilled: * Patients currently participating in any other clinical trial. * Known history of allergy or reaction to any component of the study treatment formulation. * Malignancy of any kind. * Patients with prior or ongoing treatment with benralizumab.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic obstructive pulmonary disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease T2-high asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic obstructive pulmonary disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    36 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Research Site

    RECRUITING

    Anhui, China

  • Research Site

    RECRUITING

    Anning, China

  • Research Site

    RECRUITING

    Beijing, China

  • Research Site

    RECRUITING

    Binzhou, China

  • Research Site

    RECRUITING

    Changzhou, China

  • Research Site

    RECRUITING

    Fenyang, China

  • Research Site

    RECRUITING

    Guangdong, China

  • Research Site

    RECRUITING

    Guangzhou, China

  • Research Site

    RECRUITING

    Hangzhou, China

  • Research Site

    RECRUITING

    Huzhou, China

  • Research Site

    RECRUITING

    Jiaxing, China

  • Research Site

    RECRUITING

    Jinan, China

  • Research Site

    RECRUITING

    Jinhua, China

  • Research Site

    RECRUITING

    Jining, China

  • Research Site

    RECRUITING

    Jiyuan, China

  • Research Site

    RECRUITING

    Kunshan, China

  • Research Site

    RECRUITING

    Linyi, China

  • Research Site

    RECRUITING

    Mianyang, China

  • Research Site

    RECRUITING

    Nanbu, China

  • Research Site

    RECRUITING

    Nanchang, China

  • Research Site

    RECRUITING

    Nanjing, China

  • Research Site

    RECRUITING

    Ningbo, China

  • Research Site

    RECRUITING

    Shanghai, China

  • Research Site

    RECRUITING

    Shanxi, China

  • Research Site

    RECRUITING

    Shenzhen, China

  • Research Site

    RECRUITING

    Shijiazhuang, China

  • Research Site

    RECRUITING

    Suining, China

  • Research Site

    RECRUITING

    Taiyuan, China

  • Research Site

    RECRUITING

    Weifang, China

  • Research Site

    RECRUITING

    Wuhan, China

  • Research Site

    RECRUITING

    Wuxi, China

  • Research Site

    RECRUITING

    Xi'an, China

  • Research Site

    RECRUITING

    Xiamen, China

  • Research Site

    RECRUITING

    Zhangjiagang, China

  • Research Site

    RECRUITING

    Zhengzhou, China

  • Research Site

    RECRUITING

    Zhenjiang, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.